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ABSTRACT	  
Background:	   Between	   1994	   and	   2004	   the	   prevalence	   of	   diabetes	   in	   Jordan	   increased	   from	   13.0%	   to	  
17.1%.	   Among	   individuals	   with	   diabetes	   in	   Jordan,	   54%	   had	   unsatisfactory	   blood	   glucose	   control.	   In	  
response	   to	   the	   diabetes	   epidemic	   in	   Jordan,	   the	   National	   Center	   for	   Diabetes	   Endocrinology	   and	  
Genetics	  (NCDEG)	  was	  founded.	  NCDEG’s	  primary	  objective	  is	  to	  improve	  diabetes	  treatment	  in	  Jordan,	  
and	  does	   so	  by	  offering	   treatment	   facilities	   specific	   for	   diabetic	   patient	   needs.	   In	   2008	  NCDEG	  began	  
implementation	   of	   an	   integrated	   patient	   education	   strategy	   (IPE).	   Certified	   diabetes	   educators	   joined	  
NCDEG	   and	   were	   provided	   space	   within	   each	   diabetes	   clinic	   within	   the	   center	   for	   individual	   patient	  
counseling.	   The	   program	  was	   fully	   implemented	   by	   2009.	   However,	   NCDEG	   did	   not	   have	   a	   feedback	  
mechanism	   to	   assess	   the	   effectiveness	   of	   the	   program.	  Methods:	   To	   assess	   the	   effectiveness	   of	   the	  
integrated	   education	   program	   and	   assess	   whether	   response	   differed	   between	   gender,	   we	   sampled	  
patients	  attending	  NCDEG	  prior	  IPE	  implementation	  (01Jan2006	  –	  31Dec2007)	  (P1)	  and	  patients	  enrolled	  
at	  NCDEG	  after	  implementation	  (01Jan2010	  –	  31Dec2011)	  (P2).	  Patients	  eligible	  for	  study	  were	  diabetic,	  
were	   new	   patients	   within	   each	   time	   period,	   had	   at	   least	   three	   visits	   to	   the	   center	   within	   each	   time	  
period,	  and	  could	  not	  be	  pregnant	  during	  the	  periods	  of	  study.	  To	  collect	  data,	  an	  iPad	  application	  was	  
developed	  to	  extract	  data	  from	  charts	  on	  the	  first	  3	  visits	  to	  the	  center.	  A	  team	  of	  physicians	  at	  NCDEG	  
was	   assembled	   to	   collect	   the	   data.	   Chi-­‐square	   tests	   and	   F-­‐Tests	   were	   used	   to	   compare	   categorical	  
variables	   and	   t-­‐tests	   were	   used	   to	   compare	   continuous	   variables.	   A	   linear	   model	   was	   created	   with	  
period	  being	  the	  primary	  predictor	  variable.	  Results:	  Univariate	  analyses	  showed	  that	  change	  in	  HbA1c	  
did	  not	  differ	  between	  P1	  (-­‐1.54	  SD=1.81)	  and	  P2	  (-­‐1.52	  SD=1.85)	  (p=0.894).	  Univariate	  analysis	  showed	  
that	   change	   in	  HbA1c	  differed	  between	   females	   (-­‐1.30	  SD=1.80)	  and	  males	   (-­‐1.77	  SD=1.84)	   (p<0.001).	  
Univariate	  analysis	  showed	  the	  change	  in	  HbA1c	  was	  different	  between	  females	  and	  males	  within	  each	  
period:	   female	   P1	   (-­‐1.26	   SD=1.77)	   versus	   male	   P1	   (-­‐1.80	   SD=1.81)	   (p=0.007)	   and	   female	   P2	   (-­‐1.32	  
SD=1.82)	   versus	   male	   P2	   (-­‐1.74	   SD=1.87)	   (p=0.019).	   When	   controlling	   for	   Gender,	   Age,	   Duration	   of	  
Diabetes,	   HbA1c	   at	   V1,	   Time	   between	   V2	   and	   V3,	   BMI	   between	   V1	   and	   V3	   Chronic	   Kidney	   Disease	  
status,	  Hyperthyroidism	  status,	  Sulfonylurea	  prescription,	  MIX	  Insulin	  prescription	  and	  NPH	  prescription	  
the	  average	  change	  in	  HbA1c	  in	  P2	  was	  -­‐0.177	  (SD=0.012)	  higher	  than	  in	  P1	  and	  the	  average	  change	  of	  
male	   HbA1c	   decrease	   was	   -­‐0.222	   (SD=0.088)	   higher	   than	   for	   females.	   Conclusions:	   Glucose	   control	  
improved	   after	   implementation	   of	   diabetes	   education	   intervention	   and	   this	   improvement	   was	   more	  
pronounced	  among	  male	  than	  female	  patients.	  




Type	  2	  Diabetes	  mellitus	  (T2DM)	  is	  a	  metabolic	  disorder	  characterized	  by	  chronic	  
hyperglycemia	  (high	  blood	  glucose	  level)	  attributed	  to	  insulin	  resistance	  and	  eventual	  decreases	  
in	  insulin	  production	  levels	  (1).	  High	  blood	  glucose	  levels	  are	  associated	  with	  dysfunction	  and	  
damage	  of	  endothelial	  cells	  which	  form	  the	  thin	  layer	  of	  cells	  that	  line	  the	  interior	  surface	  of	  
blood	  vessels	  (2).	  As	  a	  result	  of	  endothelial	  damage,	  through	  microvascular	  and	  macrovascular	  
complications	  T2DM	  is	  associated	  with	  significant	  increases	  in	  morbidity	  and	  mortality	  (3).	  
Major	  macrovascular	  complications	  include	  coronary	  artery	  disease	  (4),	  peripheral	  artery	  
disease	  (5),	  and	  stroke(6).	  Major	  microvascular	  complications	  include	  retinopathy	  (7),	  which	  
can	  lead	  to	  blindness	  (8),	  nephropathy	  (9),	  which	  can	  lead	  to	  renal	  failure	  (10),	  and/or	  
neuropathy	  (11),	  which	  can	  lead	  to	  limb	  amputation	  (12),	  all	  of	  which	  contribute	  to	  significant	  
morbidity	  and	  mortality	  (13).	  The	  lack	  of	  blood	  glucose	  control	  is	  the	  underlying	  reason	  for	  
many	  of	  the	  complications	  associated	  with	  diabetes	  (14).	  If	  patients	  with	  diabetes	  achieve	  
blood	  glucose	  control,	  endothelial	  cell	  damage	  will	  not	  be	  as	  severe,	  and	  the	  risk	  for	  developing	  
diabetes	  complications	  is	  significantly	  reduced	  (15).	  	  
Glycemic	  Control	  	  
T2DM	  can	  be	  diagnosed	  through	  several	  tests	  including	  (glycosylated	  hemoglobin)	  
HbA1c	  test,	  fasting	  plasma	  glucose	  (FPG)	  tests,	  as	  well	  as	  an	  oral	  glucose	  tolerance	  test	  (OGTT)	  
(16,	  17).	  An	  HbA1c	  of	  ≥6.5%,	  a	  FPG	  ≥125	  mg/dL,	  or	  an	  OGTT	  ≥200	  mg/dL	  are	  indicative	  of	  
diabetes	  (17).	  Of	  the	  three	  tests,	  HbA1c	  provides	  a	  measure	  of	  long-­‐term	  blood	  glucose	  levels,	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as	  it	  is	  representative	  of	  average	  blood	  glucose	  over	  3	  months	  (18).	  It	  also	  does	  not	  require	  that	  
patients	  take	  preparative	  steps	  before	  the	  test,	  reducing	  patient	  burden	  (19).	  	  HbA1c	  tests	  are	  
provided	  to	  all	  patients	  being	  treated	  at	  the	  National	  Center	  for	  Diabetes	  Endocrinology	  and	  
Genetics	  (NCDEG)	  as	  they	  are	  cost-­‐effective,	  easily	  administered,	  and	  do	  not	  require	  special	  
preparation	  of	  the	  patient.	  	  
On	  A	  Global	  Scale	  
In	  2000,	  it	  was	  estimated	  that	  by	  2030,	  nearly	  366	  million	  people	  would	  have	  T2DM	  
(20),	  however	  we	  approached	  that	  prevalence	  by	  2011	  beating	  projections	  by	  19	  years,	  and	  
now	  it	  is	  predicted	  that	  by	  2030	  530	  million	  people	  will	  be	  afflicted	  with	  diabetes	  (21).	  As	  of	  
2010,	  T2DM	  accounted	  for	  4.6	  million	  deaths	  in	  2011	  for	  those	  between	  the	  ages	  of	  20-­‐70,	  
which	  represents	  8.2%	  of	  the	  mortality	  in	  that	  age	  group	  (22).	  Diabetes	  has	  now	  become	  the	  
most	  common	  non-­‐communicable	  disease	  around	  the	  world	  (23).	  	  
In	  addition	  to	  contributing	  to	  morbidity	  and	  mortality,	  T2DM	  is	  associated	  with	  
significant	  economic	  burdens	  that	  have	  increased	  pressure	  on	  already	  overextended	  healthcare	  
systems,	  especially	  in	  developing	  countries	  with	  limited	  healthcare	  recourses	  (13).	  As	  of	  2010,	  
the	  global	  healthcare	  costs	  attributed	  to	  T2DM	  were	  376	  billion	  USD,	  and	  are	  projected	  to	  
reach	  490	  billion	  USD	  by	  2030	  (24).	  That	  represents	  nearly	  11%	  of	  total	  global	  healthcare	  costs.	  
A	  major	  contributor	  to	  the	  increasing	  prevalence	  of	  T2DM	  has	  been	  rapid	  urbanization	  
of	  many	  developing	  countries	  that	  have	  experienced	  the	  greatest	  increases	  in	  incidence	  and	  
prevalence	  of	  T2DM	  (25-­‐27).	  Urbanization	  and	  economic	  development	  have	  contributed	  to	  
more	  sedentary	  lifestyles	  as	  well	  as	  high	  calorie	  diets,	  that	  have	  contributed	  to	  increasing	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prevalence	  of	  obesity,	  a	  major	  risk	  factor	  for	  diabetes	  (28).	  Furthermore,	  as	  T2DM	  has	  a	  late	  
age	  of	  onset	  (29),	  as	  populations	  have	  aged,	  so	  has	  the	  prevalence	  of	  T2DM.	  	  
The	  diabetes	  epidemic	  in	  Jordan	  
Between	  1994	  and	  2004	  the	  age	  standardized	  prevalence	  of	  diabetes	  in	  Jordan	  rose	  
from	  13.0%	  to	  17.1%	  (30).	  	  The	  most	  dramatic	  increases	  in	  prevalence	  occurred	  in	  the	  50-­‐59	  
years	  and	  older	  than	  60	  years	  age	  categories	  (30).	  As	  of	  2004,	  nearly	  54%	  of	  individuals	  with	  
diabetes	  in	  Jordan	  had	  unsatisfactory	  glycemic	  control	  as	  indicated	  by	  an	  HbA1c	  greater	  than	  
7.5%	  as	  defined	  by	  the	  study	  (30).	  With	  these	  dramatic	  increases	  in	  diabetes,	  a	  National	  
Strategy	  Committee	  on	  Diabetes,	  Obesity,	  and	  Dyslipidemia	  (NSCDOD)	  was	  initiated	  by	  the	  
Jordanian	  government,	  and	  is	  headed	  by	  Former	  Minister	  of	  Health	  Kamel	  Ajlouni.	  With	  the	  
goal	  of	  identifying	  the	  cause	  for	  the	  rapid	  increase	  in	  prevalence,	  the	  NSCDOD	  identified	  several	  
factors	  associated	  with	  the	  increasing	  prevalence	  of	  T2DM	  including	  rapid	  urbanization	  
contributing	  to	  sedentary	  lifestyle,	  coupled	  with	  Jordanian	  specific	  cultural	  practices.	  Once	  such	  
practice	  included	  the	  excess	  consumption	  of	  the	  calorie	  rich	  native	  Jordanian	  dish,	  Mansaf	  that	  
is	  composed	  of	  rice,	  lamb	  cooked	  with	  fermented	  dried	  yogurt,	  and	  garnished	  with	  fried	  pine	  
nuts.	  Another	  cultural	  factor	  identified	  as	  contributing	  to	  the	  increasing	  prevalence	  of	  diabetes	  
included	  the	  cultural	  emphasis	  of	  displaying	  generosity	  to	  guests	  as	  indicated	  by	  serving	  calorie	  
rich	  foods.	  OZ	  was	  able	  to	  attend	  two	  NSCDOD	  meetings	  in	  which	  the	  rollout	  of	  a	  nationwide	  
education	  program	  was	  discussed.	  	  
As	  a	  result	  of	  initiatives	  like	  the	  formation	  of	  the	  NSCDOD,	  the	  Jordanian	  government	  
also	  moved	  to	  develop	  facilities	  and	  increase	  capacity	  and	  expertise	  for	  the	  treatment	  of	  
diabetes.	  This	  resulted	  in	  the	  founding	  of	  The	  National	  Center	  for	  Diabetes,	  Endocrinology,	  and	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Genetics	  (NCDEG),	  a	  center	  in	  Amman,	  Jordan	  that	  treats	  T2DM	  and	  T2DM	  related	  
complications.	  NCDEG	  physicians	  treating	  T2DM	  follow	  the	  American	  Diabetes	  Association	  
guidelines	  for	  diabetes	  treatment	  (31).	  	  
NCDEG	  Integrated	  Diabetes	  Patient	  Education	  Program	  
In	  2008,	  after	  recognizing	  that	  patients	  were	  using	  their	  medications	  incorrectly,	  an	  
integrated	  patient	  education	  program	  (IPEP)	  was	  implemented	  that	  provided	  patients	  with	  
educational	  material	  on	  diabetes,	  individualized	  instruction	  from	  diabetes	  educators	  on	  use	  of	  
treatment,	  and	  dietary	  and	  lifestyle	  advice.	  The	  program	  was	  fully	  implemented	  by	  2010.	  The	  
program’s	  aim	  was	  to	  provide	  diabetes	  patients	  with	  a	  comprehensive	  understanding	  of	  how	  to	  
properly	  manage	  their	  diabetes.	  	  
After	  interviewing	  the	  founding	  head	  of	  the	  IPEP	  as	  well	  as	  staff,	  and	  administrators	  that	  
worked	  at	  the	  center	  before	  and	  after	  implementation	  of	  IPEP,	  it	  was	  noted	  that	  several	  
important	  changes	  occurred	  as	  a	  result	  of	  IPEP	  included:	  1)	  the	  establishment	  of	  a	  Diabetes	  
Education	  Department	  as	  a	  sub-­‐department	  of	  the	  Nursing	  Department,	  2)	  the	  employment	  
and	  assignment	  of	  certified	  diabetes	  educators	  (CDE)	  to	  each	  diabetes	  clinic,	  3)	  the	  assignment	  
of	  a	  room	  within	  each	  clinic	  specifically	  designated	  for	  patient	  counseling	  by	  CDEs.	  	  In	  addition	  
to	  providing	  patients	  with	  educational	  material	  that	  included	  booklets	  prepared	  in	  Arabic,	  CDEs	  
showed	  patients	  how	  to	  use	  their	  medication,	  advised	  them	  on	  when	  to	  take	  their	  medication,	  
and	  provided	  patients	  the	  opportunity	  to	  purchase	  a	  subsidized	  glucose	  monitor	  for	  10	  
Jordanian	  Dinars	  (14	  USD)	  from	  the	  NCDEG’s	  pharmacy.	  If	  patients	  purchased	  the	  glucose	  
monitor,	  had	  one	  available,	  or	  planned	  to	  purchase	  one,	  the	  CDEs	  provided	  patients	  with	  a	  
chart	  to	  be	  filled	  out	  by	  patients.	  The	  chart	  asked	  patients	  to	  take	  readings	  of	  their	  blood	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glucose	  levels	  throughout	  the	  day	  for	  one	  week	  –	  asking	  patients	  to	  take	  a	  reading	  before	  and	  
after	  every	  meal,	  before	  they	  sleep,	  and	  once	  they	  wake	  up.	  After	  the	  first	  week	  of	  readings,	  
patients	  were	  asked	  to	  come	  back	  to	  the	  clinic	  and	  provide	  the	  completed	  chart	  to	  the	  CDEs.	  
CDEs	  were	  empowered	  by	  the	  NCDEG	  administration	  to	  adjust	  diabetes	  medication	  dosages	  
and	  time	  of	  diabetes	  medications	  administration	  based	  on	  their	  analysis	  of	  the	  chart.	  After	  the	  
second	  meeting	  with	  the	  CDE,	  patients	  were	  asked	  to	  continue	  monitoring	  their	  blood	  glucose	  
and	  fill	  out	  a	  subsequent	  chart	  that	  only	  required	  three	  daily	  measures.	  In	  subsequent	  visits	  
with	  the	  CDEs,	  usually	  when	  patients	  came	  to	  the	  center	  for	  follow-­‐up	  with	  a	  physician,	  patients	  
were	  asked	  to	  provide	  their	  charts	  to	  the	  CDEs	  at	  which	  point	  CDEs	  would	  review	  the	  chart	  and	  
ensure	  patients	  were	  using	  their	  medication	  properly	  and	  that	  their	  questions	  were	  answered.	  
The	  most	  extensive	  meeting	  with	  the	  CDEs	  occurred	  at	  the	  first	  visit	  (right	  after	  first	  physician	  
visit)	  and	  second	  visit	  (1	  week	  after	  first	  physician	  visit),	  with	  briefer	  meetings	  afterwards	  
during	  subsequent	  physician	  follow-­‐up	  visits.	  	  As	  of	  2012,	  NCDEG	  did	  not	  have	  a	  feedback	  
mechanism	  in	  place	  to	  assess	  the	  success	  of	  IPEP.	  	  
To	  understand	  the	  effectiveness	  of	  IPEP	  and	  provide	  NCDEG	  with	  an	  assessment	  of	  the	  
programs	  efficacy,	  we	  retrospectively	  studied	  HbA1c	  control	  in	  patients	  treated	  in	  NCDEG	  
during	  2006-­‐07	  and	  2010-­‐11,	  before	  and	  after	  implementation	  of	  the	  program.	  	  
OBJECTIVE	  
	  The	  primary	  objective	  of	  the	  study	  was	  to	  compare	  the	  diabetes	  treatment	  outcomes	  of	  
diabetic	  patients	  in	  two	  time	  periods	  as	  assessed	  by	  change	  in	  HbA1c	  levels,	  before	  and	  after	  
implementation	  of	  a	  health	  worker-­‐led	  patient	  support	  program,	  in	  a	  public	  diabetes	  treatment	  
center	  in	  Amman	  Jordan.	  We	  hypothesized	  that	  patients	  treated	  in	  IPEP	  would	  achieve	  greater	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decreases	  in	  HbA1c	  compared	  to	  patients	  not	  treated	  in	  the	  program.	  Our	  secondary	  objective	  
was	  to	  understand	  whether	  males	  and	  females	  responded	  differently	  to	  diabetes	  treatment	  
offered	  at	  the	  NCDEG,	  and	  in	  what	  way	  did	  responses	  differ.	  Finally,	  we	  aimed	  to	  gain	  a	  snap	  
shot	  of	  patient	  characteristics	  upon	  first	  being	  treated	  at	  the	  center,	  to	  better	  understand	  the	  
characteristics	  of	  patients	  with	  diabetes	  being	  served	  by	  Jordan’s	  NCDEG.	  	  
METHODS	  
Study	  Location	  
The	  NCDEG	  was	  established	  in	  Amman,	  the	  capital	  of	  Jordan,	  for	  comprehensive	  
preventative	  and	  clinical	  services	  in	  the	  fields	  of	  diabetes,	  endocrinology	  and	  genetic	  disorders.	  
NCDEG	  receives	  patients	  from	  every	  governorate	  of	  the	  country	  through	  both	  physician-­‐referral	  
and	  self-­‐referral.	  The	  center	  is	  composed	  of	  13	  clinics,	  the	  three	  largest	  primarily	  treat	  diabetes.	  
All	  the	  patients	  with	  diabetes	  seen	  by	  the	  center	  are	  treated	  in	  the	  diabetes	  clinics.	  Each	  
diabetes	  clinic	  is	  composed	  of	  an	  endocrinologist,	  an	  endocrinologist	  fellow,	  a	  team	  of	  primary	  
care	  physicians,	  a	  nursing	  staff,	  a	  nutritionist,	  and	  a	  laboratory	  technician.	  Patients	  are	  first	  
assessed	  by	  a	  nurse	  who	  takes	  anthropometric	  measures	  and	  records	  all	  current	  medications.	  A	  
patient	  then	  has	  their	  HbA1c	  measured,	  and	  is	  then	  seen	  by	  a	  primary	  care	  physician	  who	  
records	  a	  full	  patient	  history,	  assesses	  the	  patient’s	  status,	  and	  prescribes	  necessary	  
medications.	  Either	  the	  head	  endocrinologist	  or	  the	  endocrinologist	  fellow	  approves	  the	  
prescribed	  treatment	  after	  meeting	  with	  the	  patient	  and	  primary	  care	  doctor.	  After	  2008,	  after	  
meeting	  with	  a	  physician	  patients	  would	  be	  able	  to	  discuss	  their	  treatment	  and	  received	  advice	  
and	  educational	  material	  from	  a	  CDE.	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Study	  Design	  
We	  conducted	  a	  retrospective	  cohort	  records-­‐based	  study	  within	  NCDEG,	  a	  public	  T2DM	  
treatment	  center	  located	  in	  Amman,	  Jordan.	  T2DM	  treatment	  outcomes	  were	  compared	  
between	  patients	  treated	  in	  Period	  1	  (P1)	  (01Jan2006	  to	  31Dec2007)	  and	  Period	  2	  (P2)	  
(01Jan2010	  to	  31Dec2011)	  to	  assess	  whether	  the	  implementation	  of	  an	  IPEP	  that	  occurred	  
between	  the	  two	  periods	  improved	  T2DM	  treatment.	  The	  outcome	  of	  interest	  was	  change	  in	  
HbA1c	  levels	  after	  three	  visits	  to	  NCDEG.	  Data	  was	  collected	  for	  a	  minimum	  of	  three	  visits	  and	  a	  
maximum	  of	  six	  visits	  to	  the	  center.	  For	  this	  study,	  only	  data	  for	  the	  first	  three	  visits	  were	  used	  
and	  associated	  lab	  results.	  Remaining	  data	  will	  be	  used	  for	  subsequent	  studies.	  	  	  
Eligibility	  Criteria	  
Subjects	  needed	  to	  be	  new	  patients	  within	  each	  respective	  time	  period	  –	  we	  achieved	  
this	  goal	  using	  NCDEG’s	  file	  numbering	  system	  which	  allowed	  us	  to	  only	  include	  newly	  opened	  
files	  within	  each	  respective	  time	  period.	  Patients	  needed	  to	  have	  had	  a	  minimum	  of	  three	  visits	  
to	  the	  center	  within	  each	  respective	  time	  period	  to	  be	  included.	  	  Subjects	  needed	  to	  be	  at	  least	  
25	  years	  of	  age,	  and	  have	  T2DM	  as	  either	  defined	  by	  an	  HbA1c	  of	  6.5%	  or	  above	  at	  first	  visit	  or	  
indicated	  by	  the	  physician	  in	  the	  medical	  record.	  Patients	  who	  were	  pregnant	  were	  excluded	  
from	  the	  study.	  	  
Selection	  of	  Study	  Sample	  Data	  Collection	  	  
To	  identify	  and	  collect	  data,	  we	  utilized	  NCDEG’s	  records	  numbering	  system	  to	  identify	  
when	  a	  patient’s	  first	  visit	  occurred.	  Records	  numbered	  between	  5,681	  and	  18,832	  were	  
opened	  in	  P1	  and	  records	  numbered	  between	  42,244	  and	  10,7387	  were	  opened	  in	  P2.	  Using	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the	  SAS	  Proc	  ILM,	  a	  list	  of	  numbers	  was	  randomly	  generated,	  between	  5,681	  and	  18,832	  for	  P1	  
and	  between	  42,244	  and	  107,387	  for	  P2	  (Figure	  1).	  	  All	  P1	  records	  were	  in	  paper	  form,	  while	  a	  
proportion	  of	  P2	  records	  were	  electronic.	  Within	  each	  period,	  some	  of	  the	  files	  were	  inactive	  and	  stored	  
in	  an	  inaccessible	  location,	  which	  prevented	  the	  team	  from	  collecting	  data	  on	  those	  records.	  	  Inactive	  
files	  were	  of	  patients	  who	  only	  came	  to	  NCDEG	  once,	  and	  subsequently	  did	  not	  come	  back	  for	  
retreatment.	  Inactive	  files	  were	  identified	  as	  inactive	  by	  the	  team	  through	  NCDEG	  system	  for	  tracking	  
inactive	  files	  –	  in	  the	  place	  of	  an	  inactive	  file	  within	  the	  NCDEG	  filing	  system	  would	  be	  a	  form	  indicating	  
that	  file	  was	  inactive.	  Files	  were	  inactivated	  after	  two	  years	  of	  the	  first	  visit	  if	  the	  patient	  had	  not	  
returned.	  Since	  five	  years	  elapsed	  since	  the	  end	  of	  P1,	  all	  files	  that	  were	  eligible	  to	  be	  inactivated	  in	  P1	  
were	  inactivated	  by	  the	  time	  the	  study	  was	  initiated.	  However,	  when	  we	  initiated	  the	  study	  in	  2012,	  only	  
files	  opened	  in	  the	  beginning	  of	  P2	  were	  eligible	  for	  inactivation,	  where	  as	  the	  remaining	  files	  that	  would	  
have	  been	  inactivated	  had	  the	  study	  been	  conducted	  later	  would	  have	  been	  excluded	  in	  our	  study	  as	  the	  
patient	  would	  have	  only	  had	  one	  visit	  to	  the	  center	  and	  not	  met	  minimum	  eligibility	  criteria.	  
Based	  on	  preliminary	  record	  pulls	  as	  well	  as	  applying	  exclusion	  and	  inclusion	  criteria,	  we	  
recognized	  the	  eligibility	  rate	  would	  be	  relatively	  low	  –2%	  to	  15%,	  primarily	  due	  to	  the	  
requirement	  that	  patients	  have	  a	  minimum	  of	  three	  visits	  within	  each	  period.	  We	  aimed	  for	  a	  
final	  sample	  size	  of	  1000	  patients,	  500	  within	  each	  time	  period.	  To	  avoid	  the	  possibility	  of	  not	  
reaching	  the	  target	  sample,	  we	  included	  more	  than	  70%	  of	  the	  available	  records	  within	  each	  
respective	  period	  in	  the	  randomly	  generated	  list.	  For	  P1	  located	  records,	  a	  physician	  assessed	  
whether	  each	  record	  met	  the	  inclusion	  criteria.	  For	  P2	  records,	  a	  proportion	  of	  records	  were	  
captured	  electronically,	  which	  allowed	  inclusion	  to	  occur	  in	  two	  phases	  –	  a	  first	  
inclusion/exclusion	  phase	  based	  on	  the	  electronic	  data	  available,	  and	  a	  second	  
inclusion/exclusion	  phase	  based	  on	  a	  physician	  assessment	  of	  the	  physical	  record.	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Data	  Collection	  
OZ	  developed	  an	  iPad	  App	  Survey	  (IAS)	  to	  collect	  the	  data	  for	  the	  study	  (Illustrations	  
A.1-­‐A.7).	  When	  assessing	  potential	  strategies	  for	  data	  collection,	  we	  recognized	  that	  developing	  
an	  IAS	  would	  reduce	  costs	  and	  save	  time	  during	  the	  data	  collection	  process	  by	  eliminating	  the	  
need	  to	  transfer	  data	  collected	  from	  paper	  to	  electronic	  forms	  necessary	  to	  conduct	  analysis.	  It	  
would	  also	  allow	  us	  to	  scale	  up	  the	  effort	  and	  recruit	  physicians	  from	  NCDEG	  to	  join	  the	  project	  
effort.	  The	  IAS	  was	  installed	  on	  each	  iPad	  purchased	  for	  the	  study	  and	  distributed	  to	  each	  
member	  of	  the	  research	  team.	  The	  IAS	  was	  iteratively	  tested	  with	  the	  team,	  using	  feedback	  on	  
design	  and	  functionality	  to	  improve	  the	  IAS’s	  performance.	  Security	  features	  in	  the	  IAS	  included	  
data	  encryption,	  team	  member	  specific	  usernames,	  and	  password	  protected	  entry.	  
Performance	  monitoring	  features	  included	  timestamps	  that	  were	  automatically	  generated	  at	  
the	  beginning	  and	  end	  of	  each	  data	  entry.	  Data	  quality	  features	  included	  forced	  data	  entry	  
feature	  (record	  could	  not	  be	  saved	  when	  the	  minimum	  data	  fields	  for	  three	  visits	  were	  filled),	  
range	  limits	  on	  continuous	  variables,	  and	  verification	  algorithms	  for	  specified	  variables.	  We	  paid	  
particular	  attention	  to	  ease	  of	  use	  of	  the	  IAS	  by	  keeping	  data	  fields	  large,	  and	  ensuring	  that	  
colors	  and	  designs	  contrasted	  well	  to	  allow	  for	  ease	  of	  visualization	  and	  handling.	  To	  ensure	  
integrity	  of	  an	  inputted	  record,	  various	  levels	  of	  IAS	  of	  privileges	  were	  developed.	  The	  
administrator	  account	  (for	  OZ	  access)	  had	  privileges	  to	  view,	  edit,	  and	  delete	  inputted	  records	  
as	  well	  as	  access	  to	  improve	  IAE	  performance	  if	  errors	  arose	  during	  data	  collection.	  The	  
coordinator	  account	  (for	  ML	  and	  MA)	  had	  privileges	  to	  view	  and	  delete	  inputted	  records	  as	  was	  
needed	  for	  the	  development	  of	  input	  of	  Quality	  Control	  files	  (see	  Data	  Quality).	  The	  standard	  
accounts	  had	  the	  privileges	  to	  create	  records	  (ML,	  MA,	  AA,	  BM,	  AA,	  LH,	  MJ).	  Standard	  accounts	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were	  made	  for	  each	  member	  of	  the	  team	  with	  individualized	  passwords	  and	  usernames.	  Finally,	  
each	  inputted	  record	  was	  associated	  with	  a	  particular	  username,	  which	  allowed	  for	  
performance	  feedback	  used	  for	  quality	  control	  calibrations	  of	  data	  entry.	  	  
The	  IAS	  was	  used	  to	  collect	  data	  on	  a	  minimum	  of	  258	  data	  fields	  and	  a	  maximum	  of	  537	  
data	  fields	  based	  on	  how	  many	  visits	  a	  patient	  had	  to	  NCDEG	  and	  how	  many	  lab	  results	  they	  
had.	  We	  collected	  data	  on	  gender,	  age,	  height,	  duration	  of	  T2DM	  upon	  visit,	  insurance	  
coverage,	  and	  copay	  percent	  for	  each	  subject.	  We	  collected	  data	  on	  date	  of	  visit,	  weight,	  waist,	  
diastolic	  blood	  pressure,	  systolic	  blood	  pressure,	  HbA1c,	  family	  history	  of	  T2DM,	  smoking	  
status,	  19	  comorbidities,	  and	  57	  medication/supplements	  for	  each	  visit	  for	  a	  minimum	  of	  three	  
and	  a	  maximum	  of	  six.	  	  We	  collected	  data	  on	  dates	  and	  values	  of	  lab	  tests:	  LDL	  cholesterol,	  HDL	  
cholesterol,	  total	  cholesterol,	  and	  triglycerides	  for	  maximum	  of	  six	  lab	  tests.	  Data	  on	  only	  the	  
first	  three	  visits	  where	  used	  for	  this	  study,	  while	  remaining	  data	  will	  be	  used	  for	  future	  studies.	  	  
Data	  Collection	  Team	  
The	  team	  was	  composed	  of	  six	  primary	  care	  physicians	  representing	  the	  three	  diabetes	  
clinics	  within	  NCDEG.	  OZ	  initiated	  the	  project,	  founded	  the	  team,	  and	  led	  the	  research	  effort.	  
OZ	  also	  organized	  tutorial	  sessions,	  led	  team	  meetings,	  developed	  protocols	  for	  distribution,	  
and	  developed	  IAS.	  Upon	  joining	  the	  team	  and	  receiving	  the	  study	  protocol,	  the	  physicians	  
were	  provided	  with	  a	  tutorial	  on	  how	  to	  use	  the	  application	  via	  videoconference.	  Topics	  of	  the	  
tutorial	  included	  best	  practices	  for	  data	  entry,	  security,	  and	  maintenance.	  The	  tutorial	  also	  
included	  an	  overview	  of	  variable	  definitions	  and	  criteria.	  Finally,	  one	  of	  the	  physicians	  received	  
extensive	  training	  through	  additional	  videoconference	  meetings	  so	  as	  to	  have	  the	  capacity	  to	  
address	  data	  entry	  issues	  as	  they	  arose.	  Weekly	  videoconference	  meetings	  were	  held	  to	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address	  major	  issues,	  and	  issues	  that	  required	  immediate	  attention	  between	  meetings	  were	  
either	  handled	  via	  email	  or	  via	  phone	  call	  with	  OZ.	  	  
Quality	  Control	  Measures	  	  
Quality	  control	  measures	  were	  carried	  out	  during	  data	  collection	  to	  ensure	  that	  the	  final	  
dataset	  accurately	  reflected	  information	  that	  was	  present	  in	  the	  medical	  records.	  Before	  data	  
collection	  began,	  all	  physicians	  inputting	  data	  and	  determining	  exclusion/inclusion	  of	  files	  were	  
provided	  with	  a	  detailed	  study	  protocol.	  All	  the	  physicians	  participating	  in	  the	  study	  underwent	  
training	  on	  data	  input	  and	  exclusion/inclusion	  criteria.	  Before	  physicians	  could	  begin	  data	  entry,	  
they	  had	  to	  demonstrate	  their	  ability	  to	  use	  the	  iPad	  application	  developed	  for	  the	  project	  by	  
OZ	  and	  input	  a	  standard	  file	  with	  100%	  accuracy	  as	  compared	  to	  a	  previous	  entry	  of	  that	  file	  
that	  was	  prepared	  by	  the	  two	  lead	  doctors	  within	  the	  NCDEG,	  with	  any	  differences	  resolved	  
through	  agreement.	  Once	  all	  six	  team	  members	  began	  to	  enter	  patient	  records	  into	  the	  
database,	  55	  randomly	  selected	  records	  from	  the	  records	  that	  were	  included	  in	  the	  study	  were	  
selected	  as	  quality	  control	  records	  (QC).	  Two	  physicians	  independently	  entered	  the	  data	  from	  
the	  QCs	  and	  their	  independent	  entries	  were	  consolidated	  into	  one	  –	  any	  differences	  before	  
consolidation	  were	  resolved	  by	  physician	  agreement.	  The	  55	  QCs	  were	  used	  to	  measure	  an	  
inter-­‐rater	  reliability	  for	  each	  categorical	  collected	  variable	  and	  correlations	  for	  continuous	  
variables.	  The	  record	  entries	  were	  compared	  to	  QCs	  in	  real-­‐time	  via	  percent	  agreement,	  which	  
allowed	  us	  to	  assess	  the	  quality	  of	  record	  entries	  and	  take	  corrective	  action	  if	  any	  data	  entry	  
problems	  were	  identified.	  	  
Table	  A.1	  and	  Table	  A.2	   (Appendix)	  present	  measurements	  on	   the	  quality	  of	   the	  data	  
collected	   as	   compared	   to	   55	   QC	   input.	   In	   Table	   A.1	   the	   correlation	   between	   selected	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continuous	  variables	   in	  the	  original	   input	  and	  the	  QC	  input	  are	  presented.	  The	  correlation	  for	  
HbA1c	  V1,	  HbA1c	  V2,	  and	  HbA1c	  V3	  between	  original	  input	  and	  QC	  input	  is	  1.0000	  (p<0.0001),	  
1.0000	   (p<0.0001),	   and	   1.0000	   (p=0.0016)	   respectively.	   Table	   A.2	   presents	   the	   inter-­‐rater	  
reliability	   Kappa	   coefficients	   (IRRC)	   for	   several	   comorbidities	   and	   medication	   variables	   of	  
interest.	  All	  comorbidity	  and	  medication	  variables	   included	  in	  the	  finale	  model	  had	  high	  IRRC:	  
Sulfonylurea	   (IRRC=0.9242),	   NPH	   (IRRC=1.0000),	   Metformin	   (IRRC=1.000),	   CKD	   (1.000),	   and	  
Hyperthyroidism	  (IRRC=1.0000).	  
Statistical	  Analyses	  
Baseline	  variables	  were	  compared	  between	  P1	  and	  P2,	  as	  well	  as	  between	  genders	  
within	  each	  period	  using	  t-­‐tests	  for	  continuous	  variables,	  and	  χ2	  test	  for	  categorical	  
variables	  and	  Fischer’s	  exact	  tests	  when	  appropriate.	  To	  assess	  baseline	  characteristics	  and	  
changes	  in	  baseline	  characteristics	  with	  important	  covariates,	  categorical	  variables	  were	  
created	  for	  BMI	  (Normal:	  18.5≤BMI<25.0;	  Overweight:	  25.0≤BMI<30.0;	  Obese	  Class	  1:	  
30.0≤BMI<34.9;	  Obese	  Class	  2:	  35.0≤BMI<40;	  Obese	  Class	  3:	  40≤BMI),	  blood	  pressure	  
(Normal:	  Systolic<	  120	  and	  Diastolic<80;	  Prehypertension:	  120≤Systolic<140	  or	  
80≤Diastolic<90;	  Stage	  1	  –	  High:	  140≤Systolic<160	  or	  90≤Diastolic<100;	  Stage	  2	  –	  High:	  
160≤Systolic	  or	  100≤Diastolic).	  All	  study	  subjects	  were	  diabetics,	  so	  they	  need	  to	  meet	  two	  
of	  the	  following	  criteria	  to	  be	  considered	  to	  have	  metabolic	  syndrome:	  Antihypertensive	  
medication	  and/or	  high	  blood	  pressure	  (≥140	  mm	  Hg	  systolic	  or	  ≥90	  mm	  Hg	  diastolic),	  
Plasma	  triglycerides	  ≥150	  mg/dL,	  HDL	  cholesterol	  <35	  mg/dL	  in	  males	  or	  <39	  mg/dL	  in	  
females,	  or	  BMI	  >30	  kg/m2Improvement	  of	  diabetes	  status	  was	  categorized	  into	  four	  
categories.	  The	  first	  category	  was	  composed	  of	  patients	  who	  at	  the	  first	  visit	  had	  an	  HbA1c	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level	  greater	  than	  or	  equal	  to	  6.5%,	  and	  after	  three	  visits	  to	  NCDEG	  had	  dropped	  below	  the	  
6.5%	  threshold.	  The	  second	  category	  was	  composed	  of	  subjects	  who	  at	  the	  first	  clinical	  
visit	  had	  an	  HbA1c	  level	  greater	  than	  or	  equal	  to	  6.5%,	  and	  after	  three	  visits	  to	  NCDEG	  had	  
reduced	  their	  HbA1c	  levels,	  but	  not	  below	  the	  6.5%	  threshold.	  The	  third	  group	  was	  
composed	  of	  those	  whose	  HbA1c%	  increased	  in	  the	  span	  of	  three	  visits	  with	  a	  final	  
HbA1c%	  of	  higher	  or	  equal	  to	  6.5%	  -­‐	  this	  group	  was	  composed	  of	  both	  those	  who	  at	  the	  
first	  visit	  had	  an	  HbA1c	  above	  and	  below	  6.5%.	  The	  final	  category	  was	  composed	  of	  those	  
who	  had	  an	  HbA1c	  of	  below	  6.5%	  at	  first	  visit,	  and	  maintained	  that	  status	  after	  three	  visits.	  
These	  categories	  were	  chosen	  for	  their	  clinical	  relevance.	  The	  baseline	  variables	  were	  
compared	  across	  the	  four	  categories	  using	  an	  analysis	  of	  variance	  for	  continuous	  variables,	  
a	  χ2	  test	  for	  categorical	  variables,	  and	  Fischer’s	  exact	  tests	  when	  appropriate	  
The	  main	  outcome	  variable	  was	  the	  difference	  in	  HbA1c	  level	  between	  the	  first	  visit	  and	  
the	  third	  visit	  and	  the	  primary	  exposure	  variable	  of	  interest	  was	  the	  period	  in	  which	  treatment	  
was	  sought.	  We	  determined	  that	  the	  main	  outcome	  variable	  was	  normally	  distributed.	  Using	  
Proc	  GLM,	  a	  linear	  model	  was	  created	  by	  including	  all	  baseline	  measures	  available,	  including	  
comorbidities	  and	  medications	  used.	  Using	  the	  Partial	  F-­‐test,	  variables	  were	  removed	  from	  the	  
model	  in	  descending	  (i.e.	  following	  a	  backward	  stepwise	  approach)	  based	  on	  the	  highest	  non-­‐
significant	  p-­‐value	  until	  the	  removal	  of	  a	  variable	  significantly	  affected	  the	  fit	  of	  the	  model.	  The	  
main	  predictor	  of	  interest,	  period	  of	  treatment,	  was	  not	  eligible	  to	  be	  removed	  regardless	  of	  p-­‐
value.	  The	  p-­‐value	  of	  dummy	  variables	  was	  assessed	  to	  be	  the	  lowest	  p-­‐value	  within	  the	  group.	  
Dummy	  variables	  for	  a	  given	  categorical	  variable	  were	  removed	  from	  the	  model	  together.	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Quality	  of	  data	  collected	  was	  assessed	  in	  real-­‐time	  via	  percent	  agreement.	  Proc	  Corr	  was	  
used	  to	  measure	  the	  correlation	  between	  inputted	  files	  and	  QC	  files.	  Proc	  Freq	  with	  the	  Agree	  
Option	  was	  used	  to	  measure	  the	  simple	  Kappa	  coefficient	  for	  each	  categorical	  variable	  to	  assess	  
intra-­‐rater	  reliability.	  
All	  analyses	  were	  conducted	  using	  SAS	  statistical	  software	  (version	  9.2	  SAS	  Institute	  Inc.,	  
Cary,	  NC,	  USA).	  
RESULTS	  
Selected	  baseline	  characteristics	  of	  the	  765	  participants	  are	  presented	  in	  Table	  1.	  There	  
were	  323	  subjects	  in	  P1	  and	  442	  subjects	  in	  P2.	  The	  average	  age	  at	  first	  visit	  for	  P1	  was	  55.46	  
years	   (SD=9.78),	  which	  was	  statistically	  the	  same	  as	  the	  average	  age	  at	   first	  visit	   for	  P2	  56.24	  
years	  (SD=10.39)	  (p=0.295).	  The	  HbA1c	  reading	  at	  V1	  of	  9.35(%)	  (SD=2.15)	  was	  statistically	  the	  
same	  in	  P1	  and	  P2	  9.28(%)	  (SD=2.10),	  (p=0.611).	  There	  was	  a	  difference	  in	  LDL	  cholesterol	  levels	  
(p=0.043):	   131.80	  mg/dL	   (SD=34.70)	   for	   P1,	   and	   123.10	  mg/dL	   (SD=43.74)	   for	   P2.	   There	  was	  
also	   a	   difference	   in	   baseline	   systolic	   blood	   pressure:	   129.60	   mmHg	   (SD	   19.47)	   for	   P1,	   and	  
137.50	  mmHg	   (SD	   21.23)	   for	   P2.	   The	   distribution	   of	   blood	   pressure	   in	   categories	   of	  Normal,	  
Prehypertension,	  High	  Blood	  Pressure	  Stage	  1	  and	  High	  Blood	  Pressure	  Stage	  2	  was	  different	  
between	  P1	   and	  P2	   (p=0.004).	  A	   greater	   proportion	  of	   the	  patients	   had	  High	  Blood	  Pressure	  
Stage	  1	  and	  Stage	  2	   in	  P2	  compared	  to	  P1.	  The	  distribution	  of	  smoking	  status	  categories	  was	  
different	   between	   P1	   and	   P2	   (p<0.001),	   with	   a	   larger	   proportion	   in	   P2	   having	   never	   been	  
smokers	  (35.52%)	  compared	  to	  P1	  (20.12%),	  and	  as	  well	  a	  higher	  proportion	  in	  P2	  being	  current	  
smokers	   (19.91%)	   compared	   to	   P1	   (13.93%).	  More	   subjects	   in	   P1	   had	   an	   unknown	   smoking	  
status	  (58.51%)	  compared	  to	  P2	  (36.20%).	  	  Similarly,	  the	  distribution	  of	  patient	  family	  history	  of	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diabetes	  was	  different	  between	  P1	  and	  P2	  (p<0.001).	  A	  far	  greater	  proportion	  of	  the	  patients	  
had	  P1	  (44.89%)	  had	  a	  no	  family	  history	  of	  diabetes	  compared	  to	  P2	  (27.50%).	  For	  those	  with	  
enough	  data	  to	  assess	  metabolic	  syndrome,	  the	  distribution	  of	  with	  metabolic	  syndrome	  in	  P1	  
and	   P2	   was	   similar	   (p=0.724).	   The	   distribution	   of	   insurance	   copay	   amount	   was	   different	  
between	   P1	   and	   P2	   (p<0.001),	   with	   a	   larger	   proportion	   in	   P2	   having	   to	   pay	   a	   20%	   copay	  
(79.95%)	   compared	   to	   P1	   (71.88%),	   and	   a	   far	   lower	   proportion	   in	   P2	   paying	   a	   12%	   copay	  
(0.91%)	   compared	   to	   P1	   (13.44%).	   	   Baseline	   characteristics	   that	   were	   equivalent	   between	  
periods	   included	   BMI	   by	   category	   (Normal,	   Overweight,	   Obese	   Class	   1,	   Obese	   Class	   2,	   and	  
Obese	   Class	   3),	   and	   insurance	   type	   categories	   (Governmental,	   Private,	   No	   Insurance,	   and	  
Unknown).	  	  
Table	  2	  presents	  change	  in	  selected	  baseline	  characteristics	  between	  the	  first	  and	  third	  
NCDEG	  visit	  by	  period.	  The	  change	   in	  Hba1c	  was	  similar	   in	  both	  P1	  and	  P2.	   In	  P1	  the	  drop	   in	  
HbA1c	   was	   -­‐1.54(%)	   (SD=1.81),	   while	   in	   P2	   it	   was	   -­‐1.52(%)	   (SD=1.85)	   (p=0.894).	   Change	   in	  
diastolic	   and	   systolic	   blood	   pressure	   were	   also	   not	   significantly	   different	   between	   periods.	  
However,	   while	   the	   BMI	   of	   patients	   in	   P1	   decreased	   after	   3	   visits	   (-­‐0.10(%),	   SD=1.69),	   it	  
increased	   in	   P2	   after	   3	   visits	   (0.19(%),	   SD	   1.52)	   (p=0.013).	   Another	   statistically	   significant	  
change	  in	  baseline	  variable	  different	  between	  P1	  and	  P2	  was	  time	  elapsed	  between	  V1	  and	  V3.	  
While	  the	  average	  time	  elapsed	  between	  V2	  and	  V3	  in	  P1	  was	  145.90	  days	  (SD=82.69),	   it	  was	  
157.70	  days	  (SD=77.89)	  for	  P2.	  
Table	  3	  presents	  selected	  baseline	  characteristics	  of	  the	  study	  sample	  across	  gender.	  
Several	  baseline	  characteristics	  differed	  between	  males	  and	  females.	  Most	  important,	  males	  
had	  a	  higher	  baseline	  Hba1c	  of	  9.49(%)	  (SD=2.16),	  compared	  to	  females	  who	  had	  an	  average	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baseline	  HbA1c	  of	  9.13(%)	  (SD=0.018).	  Females	  at	  baseline	  were	  older	  than	  males,	  (57.15	  years,	  
SD=9.68)	  versus	  (54.67	  years,	  SD=10.45)	  (p=<0.001).	  Females	  had	  a	  higher	  baseline	  HDL	  level	  
compared	  to	  males	  (p<0.001).	  Similarly,	  females	  had	  a	  higher	  Total	  Cholesterol	  (TC)	  compared	  
to	  males	  (p=0.013).	  Females	  also	  had	  a	  higher	  Body	  Mass	  Index	  (BMI)	  (p<0.001)	  and	  a	  higher	  
systolic	  blood	  pressure	  at	  baseline	  (p<0.001)	  compared	  to	  males.	  As	  indicated	  by	  chi-­‐square	  
tests,	  the	  distribution	  of	  BMI	  categories,	  blood	  pressure	  categories,	  smoking	  status,	  and	  
metabolic	  syndrome	  status	  differed	  between	  genders.	  	  
Table	  4	  presents	  changes	  in	  selected	  baseline	  characteristics	  of	  males	  and	  females	  after	  
three	  visits	  to	  the	  center.	  There	  were	  several	  differences	  of	  interest.	  Notably,	  male	  HbA1c	  
dropped	  by	  a	  larger	  degree	  (-­‐1.77(%)	  (SD	  1.84))	  compared	  to	  female	  HbA1c	  change	  (-­‐1.30(%)	  
(SD	  1.80))	  (p<0.001).	  The	  BMI	  of	  males	  also	  dropped	  by	  a	  greater	  degree	  compared	  to	  females	  
(p<0.001),	  and	  among	  males	  less	  time	  elapsed	  between	  V1	  and	  V3	  compared	  to	  females	  
(p=0.025).	  Whereas	  males	  come	  in	  for	  V3	  appointment	  after	  146.20	  (SD=75.04)	  days,	  females	  
come	  in	  after	  159.20	  days	  (SD=84.49).	  	  	  
Table	  5	  presents	  baseline	  characteristics	  stratified	  by	  period	  and	  gender.	  It	  is	  interesting	  
to	  note	  that	  the	  differences	  between	  males	  and	  females	  with	  regards	  to	  baseline	  characteristics	  
also	  existed	  within	  each	  period.	  In	  some	  cases	  differences	  in	  baseline	  characteristics	  between	  
males	  and	  females	  differed	  only	  within	  one	  of	  the	  periods.	  Females	  had	  higher	  HDL	  levels	  
compared	  to	  males	  in	  both	  P1	  (p<0.001)	  and	  P2	  (p<0.001)	  and	  higher	  TC	  compared	  to	  males	  in	  
P2	  (p=0.042).	  In	  both	  P1	  and	  P2,	  females	  had	  a	  higher	  (p<0.001)	  BMI	  compared	  to	  males	  and	  a	  
higher	  (p<0.005)	  systolic	  blood	  pressure.	  Smoking	  status	  differed	  between	  males	  and	  females,	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with	  higher	  proportion	  of	  males	  being	  smokers	  compared	  to	  females	  (p<0.001)	  in	  both	  time	  
periods.	  Gender	  differences	  were	  also	  identified	  for	  copay	  categories	  (p=0.081),	  family	  history	  
of	  diabetes	  (p<0.001),	  and	  metabolic	  syndrome	  status	  (p<0.003)	  but	  only	  in	  P2.	  	  
Table	  6	  presents	  changes	  in	  selected	  baseline	  characteristics	  stratified	  by	  gender	  and	  
period.	  It	  is	  interesting	  to	  note	  that	  in	  both	  P1	  and	  P2	  the	  HbA1c	  of	  males	  decreased	  by	  a	  
greater	  amount	  compared	  to	  females.	  While	  in	  P1,	  the	  HbA1c	  of	  males	  decreased	  by	  1.80(%)	  
(SD=1.81),	  in	  the	  same	  period	  the	  HbA1c	  of	  females	  decreased	  by	  1.26(%)	  (SD=1.77)	  (p=0.007).	  
Similarly	  in	  P2,	  while	  the	  HbA1c	  of	  males	  decreased	  by	  1.74(%)	  (SD	  1.81),	  the	  HbA1c	  of	  females	  
decreased	  by	  1.32(%)	  (SD	  1.77)	  (p=0.019).	  While	  in	  P1,	  the	  BMI	  of	  males	  decreased	  (-­‐0.14	  kg/m2	  
(SD=1.35),	  it	  increased	  for	  females	  (0.38	  kg/m2	  (SD=1.99)).	  	  
Table	  7	  presents	  clinically	  relevant	  glucose	  control	  outcomes	  after	  three	  visits	  to	  NCDEG.	  
Subjects	  were	  categorized	  into	  one	  of	  four	  mutually	  exclusive	  categories:	  a)	  improve	  (decrease)	  
to	  an	  HbA1c	  below	  6.5(%)	  (N=103),	  b)	  improve	  (decrease)	  to	  an	  HbA1c	  above	  6.5(%)	  (N=504),	  c)	  
maintain	  an	  HbA1c	  below	  6.5(%)	  (N=27),	  or	  d)	  experience	  an	  HbA1c	  increase	  to	  above	  6.5(%)	  
(N=145).	  The	  distribution	  across	  these	  categories	  by	  period	  was	  borderline	  significant	  
(p=0.056).	  More	  patients	  improved	  to	  below	  6.5(%)	  in	  P1	  (14.86%)	  compared	  to	  P2	  (12.44%),	  
while	  more	  patients	  HbA1c	  increased	  in	  P1	  (17.03%)	  compared	  to	  P2	  (20.36%).	  Most	  patients	  in	  
both	  periods	  improved	  their	  HbA1c,	  but	  did	  not	  pass	  the	  6.5(%)	  HbA1c	  threshold:	  P1	  (65.02%)	  
and	  P2	  (63.35%).	  The	  distribution	  glucose	  control	  outcome	  by	  gender	  was	  significant	  (p=0.013).	  
More	  males	  were	  represented	  in	  the	  improved	  categories	  compared	  to	  females.	  For	  males,	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15.67%	  improved	  to	  below	  6.5(%)	  compared	  11.26%	  for	  females.	  For	  males,	  66.32%	  improved	  
to	  below	  6.5(%)	  compared	  to	  61.78%	  for	  females.	  	  
Table	  8	  presents	  the	  adjusted	  and	  unadjusted	  parameter	  estimates	  for	  the	  final	  linear	  
regression	  model	  predicting	  ΔHbA1c	  (V1-­‐V3)	  (R-­‐square=0.612).	  The	  key	  independent	  variables	  
were	  period	  and	  gender	  (differential	  response	  to	  integrated	  patient	  education	  program),	  and	  
the	  model	  was	  adjusted	  for	  the	  following	  covariates:	  duration	  of	  diabetes,	  HbA1c	  at	  first	  visit,	  
time	  elapsed	  between	  V2-­‐V3,	  change	  in	  BMI	  between	  V1-­‐V3,	  chronic	  kidney	  disease	  status,	  
hyperthyroidism	  status,	  and	  medication	  status	  for	  metformin,	  sulfonylurea,	  Mix	  Insulin	  and	  
neutral	  protamine	  Hagedorn	  (NPH)	  Insulin.HbA1c	  decreased	  by	  0.177(%)	  more	  in	  P2	  than	  in	  P1	  
(p=0.043).	  Gender	  was	  significantly	  associated	  with	  decrease	  in	  HbA1c.	  Males	  decreased	  their	  
HbA1c	  levels	  by	  0.222(%)	  more	  compared	  to	  females	  (p=0.012).	  	  
To	  assess	  which	  covariates	  contributed	  to	  the	  confounding	  of	  the	  primary	  exposure	  of	  
interest	  (period)	  toward	  the	  null,	  the	  unadjusted	  β	  estimate	  of	  period	  was	  compared	  the	  to	  the	  
β	  estimate	  of	  period	  when	  each	  covariate	  of	  the	  final	  model	  was	  added	  to	  the	  model	  one	  at	  a	  
time.	   Table	   9	   presents	   how	   the	   β	   estimate	   of	   the	   primary	   exposure	   of	   interest	   (period)	   is	  
affected	  by	  including	  the	  covariates	  in	  the	  final	  model	  one	  at	  a	  time.	  The	  β	  estimate	  for	  period	  
without	  controlling	  for	  any	  covariates	  is	  0.0180	  (p=0.894),	  while	  in	  the	  final	  model	  it	  is	  -­‐0.1770	  
(p=0.044).	  The	  changes	  in	  the	  β	  estimate	  range	  from	  0.0750	  when	  age	  is	  included	  to	  a	  change	  
of	  -­‐0.0529	  when	  Metformin	  is	  included.	  	  
	  22	  
DISCUSSION	  	  
As	  hypothesized	  before	  undertaking	  the	  study,	  period	  of	  treatment	  was	  associated	  with	  
improved	  blood	  glucose	  control	  	  (as	  assessed	  by	  ΔHbA1c	  (V1-­‐V3))	  among	  patients	  treated	  in	  the	  
center	   after	   the	   introduction	   of	   the	   IPEP	   compared	   to	   those	   treated	   before	   its	   introduction.	  	  	  
This	   finding	   supports	   NCDEG’s	   initiative	   to	   invest	   time	   and	   resources	   into	   establishing	   a	  
diabetes	  education	  program	  that	  covers	  correct	  use	  of	  medication	  as	  well	  as	  provides	  dietary	  
and	   lifestyle	  guidance	   for	  patients	  and	  offers	   them	  support	   in	  monitoring	   their	  blood	  glucose	  
levels.	  	  
Univariate	   estimates	   ΔHbA1c	   (V1-­‐V3)	   between	   periods	  were	   confounded	   towards	   the	  
null,	   as	   indicated	   by	   a	   significant	   difference	   in	   ΔHbA1c	   (V1-­‐V3)	   in	   the	   adjusted	  model,	   but	   a	  
non-­‐significant	  difference	   in	  ΔHbA1c	   (V1-­‐V3)	   in	   the	  univariate	  analysis.	  An	  analysis	   to	   identify	  
the	  major	  cofounding	  covariate	  did	  not	  indicate	  which	  covariate	  was	  the	  major	  confounder.	  The	  
univariate	   ΔHbA1c	   (V1-­‐V3)	   between	   genders	   was	   confounded	   away	   from	   the	   null,	   as	   the	  
difference	   in	   response	   between	   genders	   decreased,	   but	   remained	   significant	   in	   the	   adjusted	  
model.	  	  
An	   interesting	   outcome	   to	   note	   was	   the	   differential	   T2DM	   status	   response	   between	  
males	   and	   females.	   Males	   consistently	   performed	   better	   in	   reducing	   their	   HbA1c	   –	   their	  
response	  to	  treatment	  was	  better	  in	  both	  periods,	  and	  better	  when	  combining	  all	  males	  in	  P1	  
and	  P2	   to	   compare	  with	  all	   females	   in	  P1	  and	  P2.	   It	   is	   unclear	  why	  male	  diabetes	   treatment	  
response	   is	   better	   in	   this	   sample.	   Studies	   conducted	   on	   different	   samples	   outside	   of	   Jordan	  
have	  shown	  that	  females	  respond	  differently	  to	  diabetes	  and	  diabetes	  treatment	  compared	  to	  
males	  (32,	  33).	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While	  we	  do	  not	  know	  why	  male	  response	  to	  treatment	  of	  diabetes	  is	  better	  compared	  
to	  female	  response,	  both	  overall	  and	  within	  each	  period	  –	  we	  can	  speculate	  that	  it	  may	  have	  to	  
do	   with	   differential	   patient-­‐physician	   relationships	   across	   gender	   (34).	   Males	   may	   respond	  
more	  positively	  when	  treated	  by	  a	  male	  physician	  compared	  to	  females	  (34).	  Within	  the	  center,	  
there	  were	  2	  male	  physicians	  for	  every	  female	  physician	  treating	  T2DM.	  It	  is	  also	  possible	  that	  
males	  receive	  more	  family	  support	  when	  they	  are	  diagnosed	  with	  diabetes	  (35).	  Culture	  could	  
also	   play	   a	   major	   role	   in	   the	   physician	   patient	   dynamic.	   While	   observing	   physician-­‐patient	  
interaction	   at	   NCDEG,	  we	   noticed	   that	  male	   diabetic	   patients	   often	   came	  with	   their	   wife	   or	  
daughter.	  While	  meeting	  with	  the	  physician,	  the	  wife	  or	  daughter	  would	  ask	  the	  physicians	  very	  
specific	   questions	   regarding	   the	   appropriate	   diet	   for	   the	   father	   or	   husband	   as	   they	   would	  
usually	   prepare	   the	   meals.	   It	   is	   possible	   that	   since	   males	   primarily	   rely	   on	   their	   wives	   or	  
daughters	   for	   their	   diet	   selection,	   they	  may	   likely	   adhere	   to	   a	   recommended	   diet.	  Whereas	  
females	  would	  not	  have	   that	   advantage	  –	  as	   they	  would	  prepare	   the	   food,	   they	  may	  be	   less	  
likely	   to	   stop	   preparing	   specific	   foods	   on	   account	   of	   their	   diabetes.	   Perhaps	   the	   greater	  
decrease	   in	   HbA1c	   of	   males	   could	   be	   attributed	   to	   the	   fact	   that	   males	   had	   higher	   baseline	  
HbA1c	   levels,	   however	   in	   the	   multivariate	   linear	   model,	   the	   effect	   of	   gender	   remained	  
statistically	  significant	  even	  after	  adjusting	   for	  variables	   that	  were	  differential	  between	  males	  
and	   females	   at	   baseline,	   including	   HbA1c	   at	   visit	   1.	   Another	   potential	   explanation	   is	   that	  
females	  had	  a	  higher	  BMI	  at	  baseline,	  which	  could	  make	  achieving	  lower	  HbA1c	  more	  difficult	  
(36).	  
We	  also	  collected	  compressive	  data	  on	  baseline	  characteristics	  that	  will	  provide	  NCDEG	  
with	   an	   improved	   understanding	   of	   incoming	   patient	   characteristics.	   It	   is	   interesting	   to	   note	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that	   at	   baseline,	   patients	   came	   to	   the	   center	   with	   an	   HbA1c	   nearly	   3.0(%)	   higher	   than	   the	  
threshold	   for	   diabetes	   diagnosis	   at	   6.5(%).	   The	  HbA1c	   of	   patients	  was	   beyond	  unsatisfactory	  
control	   of	   blood	   glucose,	   which	   would	   suggest	   that	   mechanisms	   should	   be	   developed	   for	  
identifying	  diabetes	  in	  patients	  earlier.	  	  
Finally,	  as	  Table	  7	  presents,	  we	  were	  able	  to	  show	  that	  nearly	  two-­‐thirds	  of	  all	  diabetes	  
patients	   improved	  their	  HbA1c	  after	  three	  visits,	  but	  did	  not	  pass	  the	  6.5(%)	  threshold.	  There	  
was	  also	  a	   large	  proportion	  of	  the	  patients	  whose	  diabetes	  status	  worsened	  as	   indicated	  by	  a	  
higher	  HbA1c	  after	  three	  visits.	  This	  was	  particularly	  pronounced	  in	  females.	  	  
There	  are	  several	  important	  study	  limitations	  and	  strengths	  that	  are	  worth	  mentioning.	  
Because	  this	  was	  a	  records	  review	  study	  we	  needed	  to	  rely	  on	  the	  assessment	  of	  physicians	  in	  
recording	   medication	   use	   and	   the	   presence	   of	   chronic	   conditions.	   However,	   because	   the	  
chronic	  conditions	  we	  were	  interested	  in	  would	  have	  an	  impact	  on	  diabetes	  treatment,	  if	  they	  
were	  present,	  they	  were	  likely	  to	  be	  present	  within	  the	  chart.	  The	  same	  reasoning	  applies	  for	  
data	  on	  medications	  –	  because	  we	  were	   interested	   in	   looking	  at	  medications	  associated	  with	  
diabetes,	  if	  they	  were	  not	  present	  within	  the	  chart,	  then	  the	  patient	  was	  likely	  not	  taking	  these	  
medications.	   Physicians	   at	   NCDEG	   suggested	   that	   because	   various	   diabetes	   medications	   are	  
contraindicated	   for	   specific	   comorbidities	   that	   several	   layers	   of	   comorbidity	   assessment	   and	  
medication	  assessment	  are	  in	  place	  within	  the	  center	  to	  avoid	  prescribing	  a	  medication	  that	  is	  
contraindicated.	   For	   example,	   patients	   with	   chronic	   kidney	   disease	   cannot	   be	   prescribed	  
Metformin	  as	  the	  Glucophage	  will	  deposit	  within	  the	  poorly	  functioning	  kidneys	  as	  they	  cannot	  
excrete	   it	  properly.	   	  Furthermore,	  when	  prescribing	  medications,	  physicians	  recorded	  a	   list	  of	  
	  25	  
medications	  on	  the	  chart,	  and	  then	  transferred	  to	  prescription	  pads.	  	  	  Patients	  first	  meet	  with	  a	  
nurse	  that	  records	  all	  medications	  used	  and	  comorbidities	  present	  within	  the	  chart.	  	  	  
Another	   potential	   weakness	   of	   the	   study	   is	   the	   possibility	   that	   other	   unidentified	  
changes	   in	   treatment	   of	   diabetes	   at	   NCDEG	   contributed	   to	   the	   effect	   observed.	   This	   was	  
addressed	  by	  conducting	  comprehensive	  interviews	  with	  nursing	  staff,	  medical	  staff,	  as	  well	  as	  
administrators	  who	  were	  employed	  at	   the	  center	  during	  P1	  and	  P2.	  They	  confirmed	   that	   the	  
only	  other	  major	  difference	  experienced	  between	  P1	  and	  P2	  was	  increase	  in	  patients	  treated,	  
which	   they	   speculated	   could	   be	   detrimental	   to	   the	   quality	   of	   patient	   care.	   Seeing	   as	   how	  
patients	   in	  P2	  experience	  a	  greater	  adjusted	   improvement	   in	  HbA1c	  compared	  to	  P1,	  we	  can	  
assume	  that	  the	  intervention	  may	  have	  had	  an	  even	  greater	  impact	  had	  patients	  had	  as	  much	  
time	  with	  physicians	  as	  in	  P1.	  	  
The	   major	   strengths	   of	   the	   study	   include	   the	   comprehensive	   nature	   of	   the	   data	  
collected.	  	  In	  addition	  to	  being	  able	  to	  collect	  data	  on	  anthropometric	  measures,	  we	  were	  able	  
to	  collect	  data	  on	  medications	  used,	  chronic	  conditions	  present,	  as	  well	  as	  lipid	  profiles.	  	  	  
This	  study	  brings	  up	  interesting	  questions	  that	  we	  would	  like	  to	  address	  in	  future	  
studies,	  including	  why	  treatment	  response	  is	  differential.	  As	  we	  have	  collected	  data	  on	  the	  first	  
6	  visits,	  it	  would	  be	  interesting	  to	  see	  whether	  the	  P2	  advantage	  persists	  past	  the	  third	  visit.	  It	  
would	  also	  be	  interesting	  to	  conduct	  a	  survival	  analysis	  to	  understand	  whether	  time	  to	  blood	  
glucose	  control	  is	  significantly	  different	  between	  each	  period	  (37).	  Finally,	  while	  we	  have	  noted	  
in	  the	  study	  the	  differential	  response	  between	  males	  and	  females,	  the	  reasons	  are	  not	  clear.	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TABLES	  AND	  FIGURES	  
Figure	  1	  Process	  of	  Randomization	  and	  Applying	  of	  Exclusion	  and	  inclusion	  criteria.	  
	  
a. The	  number	  of	  randomly	  generated	  number	  was	  higher	  than	  the	  number	  of	  files	  we	  aimed	  to	  collect	  because	  the	  
inclusion	  rate	  was	  highly	  variable	  in	  a	  pilot	  run	  for	  determining	  the	  amount	  of	  file	  numbers	  we	  need	  to	  generate.	  As	  a	  
result,	  more	  than	  70%	  of	  available	  numbers	  were	  generated,	  and	  records	  were	  sequentially	  pulled	  based	  on	  the	  order	  of	  
the	  generated	  numbers.	  	  
b. There	  were	  more	  inactivated	  files	  in	  Period	  1	  (P1)	  versus	  Period	  2	  (P2)	  because	  files	  are	  inactivated	  every	  two	  years	  
based	  on	  whether	  a	  patient	  only	  had	  one	  visit	  to	  the	  center.	  Since	  five	  years	  elapsed	  since	  the	  end	  of	  P1,	  all	  files	  that	  
needed	  to	  be	  inactivated	  were.	  However,	  when	  we	  initiated	  the	  study	  in	  2012,	  only	  files	  opened	  in	  the	  beginning	  of	  P2	  
were	  eligible	  for	  inactivation,	  where	  as	  the	  remaining	  files	  that	  would	  have	  been	  inactivated	  had	  the	  study	  been	  conducted	  
later	  would	  have	  been	  excluded	  in	  our	  study	  as	  the	  patient	  would	  have	  only	  had	  one	  visit	  to	  the	  center	  and	  not	  met	  
minimum	  eligibility	  criteria.	  	  
c. We	  did	  not	  reach	  all	  the	  randomly	  generated	  file	  numbers	  due	  to	  time	  constraints.	  Had	  we	  continued	  going	  through	  the	  









New	  Patient	  Files	  78,296	  	  
Period	  1:	  01Jan06	  -­‐	  31Dec07	  13,152	  
Randomly	  Generated	  Record	  Numbers	  	  10,000a	  




Files	  Not	  Located	  8,098	  
Inactiveb	  1,827	  	  
Not	  Reached	  c	  6,271	  	  
Period	  2:	  01Jan10	  -­‐	  31Dec11	  65,144	  
Randomly	  Generated	  Record	  Numbers	  48,000a	  
Files	  Located	  16,236	  	  
Included	  442	  
Excluded	  15,	  7094	  
Files	  Not	  Located	  31,810	  	  
Inactive	  b	  253	  
Not	  Reachedc	  31,557	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Table	  1:	  Selected	  Baseline	  Characteristics	  by	  Period	  (Visit	  1)	  
Characteristic	   Period	  1	  (N=323)	  b	   Period	  2	  (N=442)b	   p	  c	  
HbA1c	  (%)	   9.35	  ±	  2.15	  (323)	   9.28	  ±	  2.10	  (442)	   0.611	  
Age	  (year)	   55.46	  ±	  9.78	  (323)	   56.24	  ±	  10.39	  (442)	   0.295	  
Cholesterol	  (mg/dL)	   	   	   	  
LDL	   131.80	  ±	  34.70	  (111)	   123.10	  ±	  43.74	  (251)	   0.043d	  
HDL	   43.65	  ±	  10.73	  (109)	   43.34	  ±	  13.30	  (252)	   0.815d	  
TC	   195.4	  ±	  40.77	  (113)	  	   198.50	  ±	  49.56	  (231)	   0.537d	  
TG	  (mg/dL)	   182.9	  ±	  108.5	  (114)	   199.80	  ±	  154.70	  (257)	   0.228d	  
BMI	  (kg/m2)	   32.47	  ±	  7.58	  (308)	   32.66	  ±	  9.05	  (436)	   0.765d	  
BMI	  by	  Category	  e	   	   	   0.862	  
Normal	   23	  (7.47%)	   30	  (6.88%)	   	  
Overweight	   103	  (33.44%)	   141	  (32.34%)	   	  
Obese	  Class	  1	   101	  (32.79%)	   142	  (32.57%)	   	  
Obese	  Class	  2	   48	  (15.58%)	   81	  (18.58%)	   	  
Obese	  Class	  3	   33	  (10.71%)	   42	  (9.63%)	   	  
Blood	  Pressure	  (mmHg)	   	   	   	  
Diastolic	   78.37	  ±	  12.67	  (322)	   78.08	  ±	  13.40	  (442)	   0.761	  
Systolic	   129.60	  ±	  19.47	  (323)	   137.50	  ±	  21.23	  (442)	   <0.001	  
Blood	  Pressure	  by	  Category	  f	   	   	   0.004	  
Normal	   53	  (16.46	  %)	   57	  (12.90%)	   	  
Prehypertension	   199	  (61.80%)	   236	  (53.39%)	   	  
High	  –	  Stage	  1	   57	  (17.70%)	   121	  (27.38%)	   	  
High	  –	  Stage	  2	   13	  (4.04%)	   28	  (6.33%)	   	  
Smoking	  Status	   	   	   <0.001	  
Never	   65	  (20.12%)	   157	  (35.52%)	   	  
Current	   45	  (13.93%)	   88	  (19.91%)	   	  
Former	   24	  (7.43%)	   37	  (8.37%)	   	  
Unknown	   189	  (58.51%)	   160	  (36.20%)	   	  
Family	  History	  of	  DM	   	   	   <0.001	  
Yes	  	   29	  (8.98%)	   24	  (5.45%)	   	  
No	   145	  (44.89%)	   121	  (27.50%)	   	  
Unknown	   149	  (46.13%)	   295	  (67.05%)	   	  
Metabolic	  Syndromeg	   	   	   0.724	  
Yes	  	   37	  (48.68%)	   93	  (51.10%)	   	  
No	   39	  (51.32%)	   89	  (48.90%)	   	  
Insurance	  Type	   	   	   0.359	  
Governmental	   298	  (92.26%)	   413	  (93.44%)	   	  
Private	   7	  (2.17%)	   10	  (2.26%)	   	  
No	  Insurance	   11	  (3.41%)	   16	  (3.62%)	   	  
Unknown	   7	  (2.17%)	   3	  (0.68%)	   	  
Copay	  (%)	   	   	   <0.001	  
0	   34	  (10.63%)	   67	  (15.26%)	   	  
12	   43	  (13.44%)	   4	  (0.91%)	   	  
20	   230	  (71.88%)	   351	  (79.95%)	   	  
100	   13	  (4.06%)	   17	  (3.87%)	   	  
Abbreviations:	  HbA1c,	  Glycosylated	  Hemoglobin;	  LDL,	  Low-­‐density	  Lipoprotein;	  HDL,	  High-­‐density	  Lipoprotein;	  TC,	  Total	  Cholesterol;	  TG,	  
Triglycerides;	  BMI,	  Body	  Mass	  Index;	  DM,	  Type	  2	  Diabetes	  Mellitus	  	  
a. Table	  values	  are	  mean	  ±	  SD	  (number)	  for	  continuous	  variables	  and	  n	  (column	  %)	  for	  categorical	  variables.	  
b. Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data,	  and	  percentages	  may	  not	  sum	  to	  100%	  due	  to	  rounding.	  
c. p-­‐value	  is	  for	  student	  t-­‐test	  (continuous	  variables)	  or	  χ2	  test	  (categorical	  variables).	  
d. Variances	  not	  equal.	  	  
e. Normal:	  18.5≤BMI<25.0;	  Overweight:	  25.0≤BMI<30.0;	  Obese	  Class	  1:	  30.0≤BMI<34.9;	  Obese	  Class	  2:	  35.0≤BMI<40;	  Obese	  Class	  3:	  
40≤BMI	  
f. Normal:	  Systolic<	  120	  and	  Diastolic<80;	  Prehypertension:	  120≤Systolic<140	  or	  80≤Diastolic<90;	  Stage	  1	  –	  High:	  140≤Systolic<160	  or	  
90≤Diastolic<100;	  Stage	  2	  –	  High:	  160≤Systolic	  or	  100≤Diastolic.	  
American	  Heart	  Association	  definition	  for	  metabolic	  syndrome	  was	  used.	  All	  study	  subjects	  were	  diabetics,	  so	  they	  need	  to	  meet	  two	  of	  
the	  following	  criteria	  to	  be	  considered	  to	  have	  metabolic	  syndrome:	  Antihypertensive	  medication	  and/or	  high	  blood	  pressure	  (≥140	  mm	  
Hg	  systolic	  or	  ≥90	  mm	  Hg	  diastolic),	  Plasma	  triglycerides	  ≥150	  mg/dL,	  HDL	  cholesterol	  <35	  mg/dL	  in	  males	  or	  <39	  mg/dL	  in	  females,	  or	  
BMI	  >30	  kg/m2	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Table	  2:	  Change	  in	  Selected	  Baseline	  Characteristics	  by	  Period	  (Visit	  1	  –	  Visit3)	  
Characteristic	   Period	  1(N=323)	  b	   Period	  2(N=442)b	   p	  c	  
Δ	  HbA1c	  	   	   	   	  
Absolute	  (%)	   -­‐1.54	  ±	  1.81	  (323)	   -­‐1.52	  ±	  1.85	  (442)	   0.894	  
Percent	  (Δ%)	   -­‐14.39	  ±	  16.19	  (323)	   -­‐13.92	  ±	  16.58	  (442)	   0.700	  
Δ	  BMI	  (kg/m2)	   -­‐0.10	  ±	  1.69	  (308)	   0.19	  ±	  1.52	  (436)	   0.013d	  
Δ	  Blood	  Pressure	  (mmHg)	   	   	   	  
Diastolic	   1.21	  ±	  17.23	  (322)	   -­‐2.91	  ±	  16.76	  (442)	   0.173	  
Systolic	   -­‐2.16	  ±	  20.42	  (323)	   -­‐3.79	  21	  ±	  20.42	  (442)	   0.259	  
Time	  (days)	   	   	   	  
V1	  and	  V3	   145.90	  ±	  82.69	  (323)	   157.70	  ±	  77.89	  (442)	   0.043	  
V1	  and	  V2	   58.63	  ±	  51.34	  (323)	   61.81	  ±	  47.25	  (442)	   0.375	  
V2	  and	  V3	   87.24	  ±	  57.02	  (323)	   95.89	  ±	  61.39	  (442)	   0.048	  
Abbreviations:	  HbA1c,	  Glycosylated	  Hemoglobin;	  BMI,	  Body	  Mass	  Index	  
a. Table	  values	  are	  mean	  ±	  SD	  (number)	  for	  continuous	  variables	  and	  n	  (column	  %)	  for	  categorical	  variables.	  
b. Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data,	  and	  percentages	  may	  not	  sum	  to	  100%	  due	  to	  rounding.	  
c. p-­‐value	  is	  for	  student	  t-­‐test	  (continuous	  variables)	  or	  χ2	  test	  (categorical	  variables).	  
d. Variances	  were	  not	  equal.	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Table	  3:	  Selected	  Baseline	  Characteristics	  by	  Gender	  (Visit	  1)	  	  
Characteristic	   Female	  (N=382)	  b	   Male	  (N=383)b	   p	  c	  
HbA1c	  (%)	   9.13	  ±	  2.16	  (382)	   9.49	  ±	  2.07	  (383)	   0.018	  
Age	  (year)	   57.15	  ±	  9.68	  (383)	   54.67	  ±	  10.45	  (383)	   <0.001	  
Cholesterol	  (mg/dL)	   	   	   	  
LDL	   127.70	  ±	  43.13	  (183)	   123.7.10	  ±	  39.42	  (179)	   0.356	  
HDL	   47.60	  ±	  12.75	  (182)	   39.20	  ±	  10.88	  (179)	   <0.001d	  
TC	   203.60	  ±	  48.54	  (175)	  	   191.10	  ±	  44.31	  (169)	   0.013	  
TG	  (mg/dL)	   197.20	  ±	  174.60	  (184)	   199.80	  ±	  154.70	  (257)	   0.228d	  
BMI	  (kg/m2)	   34.98	  ±	  8.73	  (368)	   30.23	  ±	  7.51	  (376)	   <0.001d	  
BMI	  by	  Categorye	   	   	   <0.001	  
Normal	   10	  (2.72%)	   43	  (11.44%)	   	  
Overweight	   73	  (19.84%)	   171	  (45.48%)	   	  
Obese	  Class	  1	   131	  (35.60%)	   112	  (29.79%)	   	  
Obese	  Class	  2	   91	  (24.73%)	   38	  (10.11%)	   	  
Obese	  Class	  3	   63	  (17.12%)	   12	  (3.19%)	   	  
Blood	  Pressure	  (mmHg)	   	   	   	  
Diastolic	   78.73	  ±	  12.78	  (382)	   77.67	  ±	  13.38	  (382)	   0.263	  
Systolic	   137.30	  ±	  21.77	  (382)	   131.10	  ±	  19.47	  (383)	   <0.001d	  
Blood	  Pressure	  by	  Categoryf	   	   	   0.018	  
Normal	   47	  (12.30	  %)	   63	  (16.49%)	   	  
Prehypertension	   207	  (54.19%)	   228	  (59.69%)	   	  
High	  –	  Stage	  1	   102	  (26.70%)	   76	  (19.90%)	   	  
High	  –	  Stage	  2	   26	  (6.81%)	   15	  (3.93%)	   	  
Smoking	  Status	   	   	   <0.001	  
Never	   136	  (35.60%)	   86	  (22.45%)	   	  
Current	   18	  (4.71%)	   115	  (30.03%)	   	  
Former	   9	  (2.36%)	   52	  (13.58%)	   	  
Unknown	   219	  (57.33%)	   130	  (33.94%)	   	  
Family	  History	  of	  T2DM	   	   	   0.272	  
Yes	  	   21	  (5.50%)	   32	  (8.40%)	   	  
No	   133	  (34.82%)	   133	  (34.91%)	   	  
Unknown	   228	  (59.63%)	   216	  (56.69%)	   	  
Metabolic	  Syndrome	  g	   	   	   0.003	  
Yes	  	   61	  (42.07%)	   69	  (61.06%)	   	  
No	   84	  (57.93%)	   44	  (38.94%)	   	  
Insurance	  Type	   	   	   0.902	  
Governmental	   357	  (93.46%)	   354	  (92.43%)	   	  
Private	   7	  (1.83%)	   10	  (2.61%)	   	  
No	  Insurance	   13	  (3.40%)	   14	  (3.66%)	   	  
Unknown	   5	  (1.31%)	   5	  (1.31%)	   	  
Copay	  (%)	   	   	   0.396	  
0	   45	  (11.81%)	   56	  (14.81%)	   	  
12	   27	  (7.09%)	   20	  (5.29%)	   	  
20	   296	  (77.69%)	   285	  (75.40%)	   	  
100	   13	  (3.41%)	   17	  (4.50%)	   	  
Abbreviations:	  HbA1c,	  Glycosylated	  Hemoglobin;	  LDL,	  Low-­‐density	  Lipoprotein;	  HDL,	  High-­‐density	  Lipoprotein;	  TC,	  Total	  Cholesterol;	  TG,	  
Triglycerides;	  BMI,	  Body	  Mass	  Index;	  DM,	  Type	  2	  Diabetes	  Mellitus	  	  
a. Table	  values	  are	  mean	  ±	  SD	  (number)	  for	  continuous	  variables	  and	  n	  (column	  %)	  for	  categorical	  variables.	  
b. Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data,	  and	  percentages	  may	  not	  sum	  to	  100%	  due	  to	  rounding.	  
c. p-­‐value	  is	  for	  student	  t-­‐test	  (continuous	  variables)	  or	  χ2	  test	  (categorical	  variables).	  
d. Variances	  not	  equal.	  	  
e. Normal:	  18.5≤BMI<25.0;	  Overweight:	  25.0≤BMI<30.0;	  Obese	  Class	  1:	  30.0≤BMI<34.9;	  Obese	  Class	  2:	  35.0≤BMI<40;	  Obese	  Class	  3:	  40≤BMI	  
f. Normal:	  Systolic<	  120	  and	  Diastolic<80;	  Prehypertension:	  120≤Systolic<140	  or	  80≤Diastolic<90;	  Stage	  1	  –	  High:	  140≤Systolic<160	  or	  
90≤Diastolic<100;	  Stage	  2	  –	  High:	  160≤Systolic	  or	  100≤Diastolic.	  
g. American	  Heart	  Association	  definition	  for	  metabolic	  syndrome	  was	  used.	  All	  study	  subjects	  were	  diabetics,	  so	  they	  need	  to	  meet	  two	  of	  the	  
following	  criteria	  to	  be	  considered	  to	  have	  metabolic	  syndrome:	  Antihypertensive	  medication	  and/or	  high	  blood	  pressure	  (≥140	  mm	  Hg	  systolic	  
or	  ≥90	  mm	  Hg	  diastolic),	  Plasma	  triglycerides	  ≥150	  mg/dL,	  HDL	  cholesterol	  <35	  mg/dL	  in	  males	  or	  <39	  mg/dL	  in	  females,	  or	  BMI	  >30	  kg/m2	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Table	  4:	  Change	  in	  Selected	  Baseline	  Characteristics	  by	  Gender	  (Visit	  1	  –	  Visit	  3)	  
Characteristic	   Female	  1(N=382)	  b	   Male	  2(N=383)b	   p	  c	  
Δ	  HbA1c	  	   	   	   	  
Absolute	  (%)	   -­‐1.30	  ±	  1.80	  (382)	   -­‐1.77	  ±	  1.84	  (383)	   <0.001	  
Percent	  (%Δ)	   -­‐11.78	  ±	  15.94	  (383)	   -­‐16.44	  ±	  16.89	  (383)	   <0.001	  
Δ	  BMI	  (kg/m2)	   -­‐0.10	  ±	  1.75	  (368)	   -­‐0.24	  ±	  1.42	  (383)	   <0.001	  *	  
Δ	  Blood	  Pressure	  (mmHg)	   	   	   0.128	  
Diastolic	   -­‐2.71	  ±	  17.00	  (382)	   -­‐1.68	  ±	  16.98	  (382)	   	  
Systolic	   -­‐4.20	  ±	  21.09	  (382)	   -­‐1.99	  ±	  18.87	  (383)	   	  
Δ	  Time	  (day)	   	   	   	  
V1	  and	  V3	   159.20	  ±	  84.49	  (382)	   146.20	  ±	  75.04	  (383)	   0.025*	  
V1	  and	  V2	   64.76	  ±	  50.81	  (382)	   56.19	  ±	  46.82	  (383)	   0.015	  
V2	  and	  V3	   94.44	  ±	  55.24	  (383)	   90.03	  ±	  55.24	  (383)	   0.308	  
Abbreviations:	  HbA1c,	  Glycosylated	  Hemoglobin;	  BMI,	  Body	  Mass	  Index	  
a. Table	  values	  are	  mean	  ±	  SD	  (number)	  for	  continuous	  variables	  and	  n	  (column	  %)	  for	  categorical	  variables.	  
b. Numbers	  may	  not	  sum	  to	  total	  due	  to	  missing	  data,	  and	  percentages	  may	  not	  sum	  to	  100%	  due	  to	  rounding.	  
c. p-­‐value	  is	  for	  student	  t-­‐test	  (continuous	  variables)	  or	  χ2	  test	  (categorical	  variables).	  




Characteristic& Female&(N=154)&b& Male&(N=169)&b& pc& Female&(N=228)b& Male&(N=214)b& pc&
HbA1c!(%)! 9.10!±!2.19!(154)! 9.59!±!2.10!(169)! 0.041! 9.15!±!2.14!(228)! 9.41!±!2.05!(214)! 0.185!
Age!(year)! 56.34!±!9.73!(154)! 54.66!±!9.79!(169)! 0.123! 57.70!±!9.62!(228)! 54.68!±!10.97!(214)! 0.002&
Cholesterol!(mg/dL)! ! ! ! ! ! !
LDL! 133.70!±!38.07!(56)! 129.90!±!31.13!(55)! 0.561! 125.10!±!45.07!(127)! 121.00!±!42.41!(124)! 0.459!
HDL! 47.13!±!11.36!(56)! 39.98!±!8.69!(53)! <0.001& 47.81!±!13.35!(126)! 38.88!±!11.70!(126)! <0.001&
TC! 200.70!±!43.71!(59)! 189.60!±!36.81!(54)! 0.149! 205.10!±!50.94!(116)! 191.80!±!47.43!(115)! 0.042&
TG!(mg/dL)! 186.80!±!109.20!(58)! 178.90!±!108.70!(56)! 0.700! 201.90!±!171.60!(129)!! 197.80!±!133.20!(128)! 0.830*!
BMI!(kg/m2)! 35.72!±!8.97!(143)! 29.66!±!4.56!(165)! <0.001& 34.51!±!8.56!(225)! 30.68!±!9.17!(211)! <0.001&
BMI!by!Categoryf! ! ! <0.001& ! ! <0.001&
Underweight! 0!(0.00%)! 0!(0.00%)! ! 1!(0.44%)! 0!(0.00%)! !
Normal! 3!(2.10%)! 20!(12.12%)! ! 6!(2.67%)! 23!(10.90%)! !
Overweight! 27!(18.88%)! 76!(46.06%)! ! 46(20.440%)! 95(45.020%)! !
Obese!Class!1! 49(34.27%)! 52(31.52%)! ! 82!(36.44%)! 60!(28.44%)! !
Obese!Class!2! 35(24.48%)! 13(7.88%)! ! 56(24.89%)! 25(11.85%)! !
Obese!Class!3! 29(20.28%)! 4(2.42%)! ! 34(15.11%)! 8(3.79%)! !
Blood!Pressure!(mmHg)! ! ! ! ! ! !
Diastolic!! ! 79.25!±!12.48!(154)! 77.56!±!12.82!(168)! 0.231! 78.38!!±!13.00!(228)! 77.76!±!13.84!(214)! 0.627!
Systolic! 132.8x!±!21.00!(154)! 126.6x!±!17.52!(168)! 0.005*& 140.3x!±!21.81!(228)! 134.6x!±!20.24!(20.24)! 0.005&
Blood!Pressure!by!Categoryg! ! ! 0.056! ! ! 0.368!
Normal! 21!(13.64%)! 32(19.05%)! ! 26!(11.40%)! 31(14.49%)! !
Prehypertension! 90(58.44%)! 109(64.88%)! ! 117!(51.32%)! 119(55.61%)! !
High!–!Stage!1! 34(22.08%)! 23(13.69%)! ! 68(29.82%)! 53(24.77%)! !
High!–!Stage!2! 9!(5.84%)! 4(2.38%)! ! 17(7.46%)! 11(5.14%)! !
Smoking!Status! ! ! <0.001& ! ! <0.001&
Never! 36!(23.38%)! 29!(17.16%)! ! 100!(43.86%)! 57!(26.64%)! !
Current! 6!(3.90%)! 39!(23.08%)! ! 12!(5.26%)! 76!(35.51%)! !
Former! 2!(1.30%)! 22!(13.02%)! ! 7!(3.07%)! 30!(14.02%)! !
Unknown! 110!(71.43%)! 79!(46.5%)! ! 109!(47.81%)! 51!(23.83%)! !
Family!History!of!T2DM! ! ! 0.241! ! ! <0.001&
Yes!! 18!(11.69%)! 11!(6.51%)! ! 3!(1.32%)! 21!(9.91%)! !
No! 69!(44.81%)! 76!(44.97%)! ! 64!(28.07%)! 57!(26.89%)! !
Unknown! 67!(43.51%)! 82!(48.52%)! ! 161!(70.61%)! 134!(63.21%)! !
Metabolic!Syndromeh! ! ! 0.373! ! ! 0.003&
Yes!! 20!(44.44%)! 17!(54.84%)! ! 41!(41.00%)! 52!(63.41%)! !
No! 25!(55.56%)! 14!(45.16%)! ! 59!(59.00%)! 30!(36.59%)! !
Insurance!Type! ! ! 0.327! ! ! 0.813!
Governmental! 144!(93.51%)! 154!(91.12%)! ! 213!(93.42%)! 200!(93.46%)! !
Private! 1!(0.65%)! 6!(3.55%)! ! 6!(2.63%)! 4!(1.87%)! !
No!Insurance! 6!(3.90%)! 5!(2.96%)! ! 7!(3.07%)! 9!(4.21%)! !
Unknown! 3!(1.95%)! 4!(2.37%)! ! 2!(0.88%)! 1!(0.47%)! !
Copay!(%)! ! ! 0.901! ! ! 0.081&
0! 16!(10.39%)! 18!(10.84%)! ! 29!(12.78%)! 38!(17.92%)! &
12! 23!(14.94%)! 20!(12.05%)! ! 4!(1.76%)! 0!(0.00%)! &
20! 109!(70.78%)! 121!(72.89%)! ! 187!(82.38%)! 164!(77.36%)! &



















Characteristic& Female&(N=154)&b& Male&(N=169)&b& pc& Female&(N=228)b& Male&(N=214)b& pc&
Δ!HbA1c!! ! ! ! ! ! !
Absolute!(Δ)! _1.26!±!1.77!(154)! _1.80!±!1.81!(169)! 0.007& _1.32!±!1.82!(228)! _1.74!±!1.87!(214)! 0.019&
Percent!(%Δ)! _11.53!±!15.75!(154)! _17.00!±16.18!(169)! 0.002& _11.95!±!16.09!(228)! _16.01!±!17.45!(214)! 0.011&
Δ!BMI!(kg/m2)! 0.38!±!1.99!(143)! _0.14!±!1.35!(165)! 0.008*& _0.08!±!1.55!(225)! _0.32!±!1.47!(211)! 0.096!
Δ!Blood!Pressure!(mmHg)! ! ! ! ! ! !
Diastolic! _1.36!±!16.39!(154)! _1.08!±!18.01!(168)! 0.882! _3.62!±!17.30!(228)! _2.15!±!16.16!(214)! 0.361!
Systolic! _3.99!±!20.98!(154)! _0.44!±!17.86!(169)! 0.102*! _4.33!±!21.21!(228)! _3.22!±!19.58!(214)! 0.566!
Δ!Time!(day)! ! ! ! ! ! &
V1!and!V3! 149.30!±!82.15!(154)! 142.70!±!83.30!(169)! 0.473! 165.90!±!85.58!(228)! 149.00!±!67.88!(214)! 0.022*&
V1!and!V2! 61.72!±!48.85!(154)! 55.81!±!55.10!(169)! 0.299*! 66.82!±!53.31!(228)! 56.48!±!39.23!(214)! 0.020*&






















Period! ! ! ! ! 0.056!
2006_2007! 48!(14.86%)! 210!(65.02%)! 10!(3.10%)! 55!(17.03%)! !
2010_2011! 55!(12.44%)! 289!(63.35%)! 17!(3.85%)! 90!(20.36%)! !
Gender! ! ! ! ! 0.013&
Female! 43!(11.26%)! 236!(61.78%)! 18!(4.71%)! 85!(22.25%)! !














Period&& & 0.043& & 0.894&
Period&1& Reference& & Reference& &
Period&2& ?0.177&(0.089)& & 0.018&(0.134)& &
Gender!! ! 0.012! ! <0.001!
Female! Reference! ! Reference! !
Male! 60.222!(0.088)! ! 60.469!(0.132)! !
Age!(year)! 0.002!(0.001)! 0.048! 0.024!(0.006)! <0.001!
Duration!of!Diabetes!(year)! 0.037!(0.008)! <0.001! 0.028!(0.010)! <0.006!




BMI!(V3!–!V1)!(kg/m2)! 60.079!(0.079)! 0.008! 60.164!(0.042)! <0.001!
Chronic!Kidney!Disease! ! 0.025! ! 0.019!
No! Reference! ! Reference! !




No! Reference! ! Reference! !
Yes! 5.696!(1.167)! ! 3.236!(1.834)! !
Metformin! ! 0.004! ! <0.001!
No! Reference! ! Reference! !
Yes! 0.029!(0.099)! ! 0.586!(0.137)! !
Sulfonylurea! ! 0.002! ! 0.323!
Yes! Reference! ! Reference! !




No! Reference! ! Reference! !
Yes! 0.712!(0.154)! ! 0.407!(0.185)! !
NPH!Insulin! ! 0.002! ! 0.626!
Yes!! Reference! ! Reference! !










Model& Period&β&Estimate& p& Change&β&&
Period&(Univariate)& 0.0180& 0.894& !!666!
Period!(Final!Model)a! 60.1765! 0.043! 60.1945!
!Period!+!Gender! 60.0003! 0.998! 60.0183!
Period!+!Age! 60.0008! 0.995! 60.0188!
Period!+!Duration!of!Diabetes! 0.0038! 0.977! 60.0142!
Period!+!BMI!(V36V1)! 0.0720! 0.598! 0.0540!
Period!+!HbA1c!V1! 60.0309! 0.742! 60.0489!
Period!+!Time!(V36V2)! 60.0299! 0.823! 60.0479!
Period!+!Chronic!Kidney!Disease! 0.0072! 0.957! 60.0108!
Period!+!Hyperthyroidism! 0.0281! 0.835! 0.0101!
Period!+!Metformin! 60.0349! 0.794! 60.0529!
Period!+!Sulfonylurea! 0.0268! 0.842! 0.0088!
Period!+!Mix!Insulin! 0.0180! 0.893! 0.0000!
Period!+!NPH!Insulin! 0.0185! 0.891! 0.0005!
Abbreviations:!HbA1c,!Glycosylated!Hemoglobin;!V(n),!Visit!(n);!BMI,!Body!Mass!Index!
a. The!final!model!included!the!following!covariates:!gender,!age,!duration!of!diabetes,!BMI!(V36V1),!HbA1c!V1,!
Time!(V3!–!V2),!Chronic!Kidney!Disease,!Hyperthyroidism,!Metformin,!Sulfonylurea,!Mix!Insulin,!and!NPH.!!
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APPENDIX&&
Table&A1:&Correlation&of&Selected&Continuous&Variables&
Between&Gold&Standard&Quality&Control&File&Inputs&and&
Corresponding&File&Inputs&a&
Model& Pearson&Correlation&
Coefficient&&
HbA1c!(%)! !
Visit!1! 1.0000!(0.0000)!
Visit!2! 1.0000!(0.0000)!
Visit!3! 1.0000!(0.0016)!
Weight!(kg)! 0.9996!(0.0040)!
Height!(cm)! 0.9999!(0.0024)!
Date!(day)! !
Visit!1! 0.9886!(0.0205)!
Visit!2! 0.9998!(0.0028)!
Visit!3! 0.9914!(0.0187)!
Duration!of!Diabetes!(year)! 0.9828!(0.0255)!
Cholesterol!(mg/dL)! !
LDL!! 0.9784!(0.0450)!
HDL!! 0.9997(0.0055)!
TC!! 0.9808!(0.0423)!
TG!(mg/dL)! 0.9985!(0.0115)!
Copay!(%)! 0.9732!(0.0325)!
Abbreviations:!HbA1c,!Glycosylated!Hemoglobin;!LDL,!Low6
density!Lipoprotein;!HDL,!High6density!Lipoprotein;!TC,!Total!
Cholesterol;!TG,!Triglycerides!!
a. Comparing!entries!of!55!QC!file!inputs!and!original!input.!
!
Table&A2:&Selected&Inter?rater&Reliability&Coefficients&for&
Comorbidity&and&Medication&Variables&a&
Model& Inter?rater&Reliability&
Kappa&Coefficient&&
Sulfonylurea!! 0.9242!
MIX!Insulin! 0.9128!
NPH!Insulin! 1.0000!!
Metformin!! 1.0000!!
Beta6Blockers! 0.9483!
!
Hydrochlorothiazide! 0.8991!
Statin! 0.9532!
Chronic!Kidney!Disease! 1.0000!
Hyperthyroidism! 1.0000!
Osteoporosis!! 1.0000!
a. !Comparing!entries!of!55!QC!file!inputs!and!original!input.!!
! !
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&
Illustration&A.1:&Screenshot!of!Basic!Information!and!Lab!Results!Section!of!iPad!Survey!Application&
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&
Illustration&A.2:&Screenshot!of!iPad!Survey!Application!used!to!collect!data!for!the!study.!Visit!1!with!
Diabetes!Medication!Section!and!Pre6mixed!Insulin!Subsection!presented.!All!Visit!pages!include!same!data!
fields!as!Visit!1.&
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!
Illustration&A.3:&Screenshot!of!iPad!Survey!Application!used!to!collect!data!for!the!study.!Visit!1!with!Diabetes!
Medication!Section!and!Basal!Insulin!presented.!All!Visit!pages!include!same!data!fields!as!Visit!1.&
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!
!
Illustration&A.4:&Screenshot!of!iPad!Survey!Application!used!to!collect!data!for!the!study.!Visit!1!with!
Diabetes!Medication!Section!and!Short!Actin!Insulin!Subsection!presented.!All!Visit!pages!include!same!
data!fields!as!Visit!1.&
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!
Illustration&A.5:&Screenshot!of!iPad!Survey!Application!used!to!collect!data!for!the!study.!Visit!1!with!
Hypertension!Medication!Section!presented.!All!Visit!pages!include!same!data!fields!as!Visit!1.&
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!
Illustration&A.6:&Screenshot!of!iPad!Survey!Application!used!to!collect!data!for!the!study.!Visit!1!with!
Dyslipidemia!Medication!Section!presented.!All!Visit!pages!include!same!data!fields!as!Visit!1.&
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!
Illustration&A.7:&Screenshot!of!iPad!Survey!Application!used!to!collect!data!for!the!study.!Visit!1!with!
Miscellaneous!Medication!Section!presented.!All!Visit!pages!include!same!data!fields!as!Visit!1.!
&
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!
Illustration&A.8:&Screenshot!of!iPad!Survey!Application!used!to!collect!data!for!the!study.!Visit!1!with!
Supplements!Section!presented.!All!Visit!pages!include!same!data!fields!as!Visit!1.&
!
